Results 281 to 290 of about 5,782,005 (384)

Protein kinase C δ and η isoenzymes control the shedding of the interleukin 6 receptor α in myeloma cells [PDF]

, 2001
Wilfrid Thabard, M. Collette, Régis Bataille, Martine Amiot   +3 more
openalex   +1 more source

PROTEINS IN MULTIPLE MYELOMA

Journal of Biological Chemistry, 1953
Frank W. Putnam, Bernard Udin
openaire   +3 more sources

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: Application of a novel pharmacodynamic assay [PDF]

, 2016
et al,, Vij, Ravi
core   +2 more sources

A case of visceral leishmaniasis mimicking connective tissue disease

Rheumatology &Autoimmunity, EarlyView.
Yucui Li, Hongxia Yang, Tingzi Zhao, Ke Xu, Liyun Zhang   +4 more
wiley   +1 more source

Can we identify individuals at risk to develop multiple myeloma? A machine learning‐based predictive model

British Journal of Haematology, EarlyView.
Individuals who may develop multiple myeloma within 5 years. Stage I (left) identifies patient and control groups and variables that differ between them. Stage II (middle) develops a complex SGBOOST model to predict future MM patients. Stage III (right) develops a simplified model.
Moshe Mittelman, Ariel Israel, Howard S. Oster, Michael Leshchinsky, Yatir Ben‐Shlomo, Eldad Kepten, Osnat Jarchowsky Dolberg, Ran Balicer, Galit Shaham   +8 more
wiley   +1 more source

SPAG6 Promotes Multiple Myeloma Through Activation of the MAPK/ERK Signaling Pathway. [PDF]

Front Pharmacol
Li J, Yan X, Ding L, Yin J, Li P, Liu L.
europepmc   +1 more source

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

British Journal of Haematology, EarlyView.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, Kar Lok Kong, David G. Kent, Helen Lachmann, Austin Kulasekararaj, Catherine Cargo, Sinisa Savic   +15 more
wiley   +1 more source

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma. [PDF]

Future Sci OA
Pianko MJ, Gupta-Werner N, Emond B, Lefebvre P, Lafeuille MH, Cortoos A, Kaila S.   +6 more
europepmc   +1 more source

Human heat shock protein‐specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma

British Journal of Haematology, 2014
Rong Li, J. Qian, Wenhao Zhang, W. Fu, J. Du, Hua Jiang, Hui Zhang, Chunyang Zhang, H. Xi, Q. Yi, J. Hou   +10 more
semanticscholar   +1 more source

Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti‐CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies

British Journal of Haematology, EarlyView.
Daratumumab and isatuximab differentially affect plasma cell identification by anti‐CD38 detection antibodies. HB‐7 and JK36 bind to CD38 epitopes E1 and E3, respectively, and co‐staining of plasma cells in the absence of CD38‐directed drugs results in a diagonal staining pattern (top left).
Afshin Shameli, Tori Catey, Valerie Woodings, Orrin Koepke, Jonathan R. Fromm, Sindhu Cherian   +5 more
wiley   +1 more source